StreetInsider.com News Articles

Form 8-K COGNITION THERAPEUTICS For: Jun 17

Thu, 18 Jun 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260618/26663186.html

Form 8-K COGNITION THERAPEUTICS For: Jun 17

Thu, 18 Jun 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260618/26663186.html

COGNITION Therapeutics receives patent notice for zervimesine to 2045

Tue, 16 Jun 2026 07:31:31 -0400

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it has received a Notice of Allowance from the United States Patent and Trademark Office for a composition of matter patent covering a polymorphic crystalline form of its lead drug candidate, zervimesine (CT1812).

Once issued, the patent will provide protection through 2045. With a standard five-year extension, protection could extend through 2050.

The patent covers the crystalline form of zervimesine, a proprietary production process, and therapeutic methods for treating Alzheimer's disease, geographic atrophy, and dementia with Lewy bodies (DLB). According to the company, the polymorphic form contains the same molecular components as the parent compound but

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Tue, 16 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.

Titled “Crystalline forms of

Form 8-K COGNITION THERAPEUTICS For: Jun 04

Thu, 04 Jun 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260604/26602747.html

Form 8-K COGNITION THERAPEUTICS For: Jun 04

Thu, 04 Jun 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260604/26602747.html

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Mon, 01 Jun 2026 07:30:00 -0400

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition’s website.

Event: 2026 Jefferies Global Healthcare Conference
Date/Time: June 4, 2026